Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 22617334
Wang J, Beauchemin M, Bertrand R (2012) Phospho-Bcl-x(L)(Ser62) plays a key role at DNA damage-induced G(2) checkpoint. Cell Cycle 11, 2159-69 22617334
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T47-p - Bcl-xL (human)
Modsite: GTESEMEtPsAINGN SwissProt Entrez-Gene
Orthologous residues
Bcl‑xL (human): T47‑p, Bcl‑xL (mouse): T47‑p, Bcl‑xL (rat): T47‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  Namalwa (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human

S62-p - Bcl-xL (human)
Modsite: PSWHLADsPAVNGAT SwissProt Entrez-Gene
Orthologous residues
Bcl‑xL (human): S62‑p, Bcl‑xL (mouse): S62‑p, Bcl‑xL (rat): S62‑p
Characterization
Methods used to characterize site in vivo [32P] ATP in vitro, immunoassay, immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  HeLa (cervical), Namalwa (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PLK1 (human)
KINASE P38A (human)
KINASE JNK1 (human)
KINASE GSK3B (human)
KINASE GSK3A (human)
KINASE JNK2 (human)
KINASE MAPKAPK2 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase
SB203580 etoposide no effect upon treatment-induced increase
SP600125 etoposide inhibit treatment-induced increase
SB216763 etoposide inhibit treatment-induced increase
etoposide PLK1 (human) augment treatment-induced increase PLK1 siRNA inhibits
etoposide JNK1 (human) augment treatment-induced increase Jnk1 siRNA inhibits
etoposide JNK2 (human) augment treatment-induced increase JNK2 siRNA inhibits
etoposide MAPKAPK2 (human) no effect upon treatment-induced increase MAPKAPK2 siRNA no effect
P38A (human) no effect upon treatment-induced increase P38-alpha siRNA no effect
GSK3A (human) augment treatment-induced increase GSK3A siRNA inhibits
GSK3B (human) augment treatment-induced increase GSK3B siRNA inhibits
BI2536 etoposide inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  activity, induced, intracellular localization, molecular association, regulation
Effect of modification (process):  cell cycle regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
CDK1 (human) Induces cell cycle regulation microscopy-colocalization, co-immunoprecipitation

T115-p - Bcl-xL (human)
Modsite: LTSQLHItPGTAYQS SwissProt Entrez-Gene
Orthologous residues
Bcl‑xL (human): T115‑p, Bcl‑xL (mouse): T115‑p, Bcl‑xL (rat): T115‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  Namalwa (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human